Severely anemic people suffering iron overload from frequent blood transfusions may someday be able to clear iron build-up with a daily pill instead of lengthy infusions of deferoxamine mesylate (Desferal).
The new oral chelator, a compound known as ICL670, is headed for phase III trials with thalessemia and sickle cell anemia patients. It reduced iron by as much as 2.2 mg/g of liver in a randomized, open-label study conducted in Italy with 71 people suffering from thalessemia, a rare inherited form of anemia. A control group of patients receiving deferoxamine had an iron reduction of 1.2 mg/g after nine months of treatment.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!